Key Perspectives: Cilta-Cel in Multiple Myeloma
Panelists discuss how long-term CARTITUDE-1 data may change clinical practice by validating earlier use of ciltacabtagene autoleucel (cilta-cel) and informing personalized treatment strategies based on risk and disease biology.
EP: 1.Treatment Approaches in Multiple Myeloma
EP: 2.FDA Approvals for Multiple Myeloma
EP: 3.CARTITUDE-1 Baseline Demographics
EP: 4.An Overview of CARTITUDE-1
EP: 5.CARTITUDE-1 Patients
EP: 6.CARTITUDE-1 Efficacy Findings
EP: 7.CARTITUDE-1 Safety Overview
EP: 8.CARTITUDE-1 Primary Findings Discussion
EP: 9.CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 1)
EP: 10.CARTITUDE-1: Long-Term Efficacy Update From EHA 2025 (Part 2)
EP: 11.CARTITUDE-1 Update Discussion
EP: 12.Key Perspectives: Cilta-Cel in Multiple Myeloma
Long-term follow-up from CARTITUDE-1 is prompting a shift in clinical practice, including earlier consideration of chimeric antigen receptor T-cell therapy. The trial has influenced regulatory agencies to accept minimal residual disease as a surrogate for survival in new studies.
As new therapies like bispecifics and trispecific antibodies emerge, clinicians must tailor treatment sequencing. Yet, cilta-cel remains a cornerstone therapy, especially for younger, fit patients or those with high-risk features who may benefit most from its curative potential.
Ultimately, these findings challenge the long-standing notion that multiple myeloma is incurable, offering new hope and optimism to patients and clinicians alike.
